Sanggenon D(CAS: 81422-93-7)

Sanggenon D (CAS: 81422-93-7) falls under the Classification, Labelling, and Packaging (CLP) regulation in the EU, which is part of the REACH regulations. In the USA, it is regulated by the EPA and FDA concerning its use in pharmaceutical and cosmetic products. The compound must comply with specific GHS classifications for transport and storage. Manufacturers should be aware of local and international regulations to ensure compliance.

There are several alternatives to Sanggenon D, including structurally similar compounds like sanguisorbin A and sanguisorbin B. Researchers often explore isomers and related analogs as substitutes. Common alternative reagents include various coupling agents and oxidizing agents that can be used in synthetic pathways to achieve similar functional groups.

The market for Sanggenon D is growing due to its potential anti-inflammatory and analgesic properties. Research trends are focused on understanding its mechanism of action and exploring its use in treating various inflammatory diseases. Market demand is also influenced by increasing interest in natural product derivatives for drug discovery. The research is advancing towards clinical trials and new formulations.

Waste containing Sanggenon D should be collected in appropriate non-leaking containers and stored in a secure area. The waste should be disposed of through incineration or professional waste disposal services that meet regulatory standards. Environmental protection guidelines must be followed to prevent contamination of soil and water. Proper labeling and documentation are essential for waste disposal to ensure compliance with environmental regulations.